International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease

Trial Profile

International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Acronyms NVG-LIGHT
  • Sponsors Human Stem Cells Institute
  • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to completed,according to the results published in the American Journal of Cardiovascular Drugs.
    • 03 Jan 2017 Results aseesing safety and efficacy of gene therapy ,also comparing the results of this study with previous phase II/III study published in the American Journal of Cardiovascular Drugs (2016).
    • 27 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top